Lisdexamphetamine (L-lysine-D-amphetamine; sold as Vyvanse) is a psychostimulant prodrug of the phenethylamine and amphetamine chemical classes. Its molecular structure consists of dextroamphetamine coupled with the essential amino acid L-lysine. Lisdexamfetamine dimesylate is discontinued (DEA controlled substance).
Jass, Paul Alan; Johnson, Todd Jeffrey; Douglas, Jason Scott; Schiesher, Matthew Wendell. Methods and compositions for preparation of amphetamine conjugates and salts thereof. Assignee Cambrex Charles City, Inc., USA. WO 2010148305. (2010).
Popp, Karl; Meckler, Harold. Amphetamine controlled release, prodrug, and abuse-deterrent dosage forms. Assignee Chemapotheca, LLC, USA. US 20180243241. (2018).
Goudriaan, Pietertie Elisabeth; Kaiser, Jasper; Ibrahim, Hemen; Verspui, Govert Arie; Cox, Douglas Phillip. Process for the preparation of lisdexamfetamine and related derivatives. Assignee Noramco, Inc., USA. WO 2017003721. (2017).
Bauer, Michael J.; Callen, Gary Richard; Humphrey, Judi Christine; Johnson, Todd Jeffrey; Schiesher, Matthew Wendell. Methods for preparing lisdexamfetamine and its salts. Assignee Cambrex Charles City, Inc., USA. US 20120157706. (2012).
Rajamannar, Thennati; Srinivasu, Kilaru; Pawar, Sujit Sridhar; Patel, Nileshkumar Sureshbhai. Process for preparation of lisdexamphetamine. Assignee Sun Pharmaceutical Industries Limited, India. WO 2017098533. (2017).